• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

    3/28/25 7:21:13 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTC alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

    Commission File Number: 001-38773

     

    CHINA SXT PHARMACEUTICALS, INC.

    (Translation of registrant’s name into English)

     

    178 Taidong Rd North, Taizhou

    Jiangsu, China 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

    Explanatory Note

     

    China SXT Pharmaceuticals, Inc. (the “Company”) is furnishing this Form 6-K to provide its financial results for the six months ended September 30, 2024.

     

    The Company hereby furnishes the following documents as the exhibits to this report: “Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2024 and 2023” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

     

    1

     

    Exhibits

     

    Exhibit No.   Description
    99.1   Management’s Discussion and Analysis of Financial Condition and Results of Operations
    99.2   Unaudited Condensed Consolidated Financial Statements for the six months ended September 30, 2024 and 2023
    101.INS   Inline XBRL Instance Document.
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
    104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

     

    2

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: March 28, 2025

      

      China SXT Pharmaceuticals, Inc.
         
      By: /s/ Feng Zhou
      Name:  Feng Zhou
      Title: Co-Chief Executive Officer

     

      By: /s/ Simon Lim Sze Beng
      Name:  Simon Lim Sze Beng
      Title: Co-Chief Executive Officer

     

     

    3

     

    Get the next $SXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTC

    DatePrice TargetRatingAnalyst
    More analyst ratings